A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Yang, Kuo Hsiung ^a   Hendrix, Craig ^b   Bumpus, Namandje ^b   Elliott, Julie ^c   Tanner, Karen ^d   Mauck, Christine ^e   Cranston, Ross ^f   McGowan, Ian ^f   Richardson Harman, Nicola ^g   Anton, Peter A ^c   Kashuba, Angela D M ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g ALPHA STATCONSULT LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; PLACEBO; TENOFOVIR; TENOFOVIR DIPHOSPHATE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ADENINE; AGENTS USED INTRAVAGINALLY; PHOSPHONIC ACID DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY FLUID; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; MAXIMUM PLASMA CONCENTRATION; MONONUCLEAR CELL; MUCOSAL MONONUCLEAR CELL; MULTICENTER STUDY; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PLASMA HALF LIFE; RANDOMIZED CONTROLLED TRIAL; RECTAL MUCOSAL FLUID; RECTUM BIOPSY; RECTUM MUCOSA; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VAGINA MUCOSA; VAGINAL MUCOSAL FLUID; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RECTAL DRUG ADMINISTRATION;

ADENINE; ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; TENOFOVIR; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84908592598     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106196     Document Type: Article

References (34)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3001187&tool=pmcentrez&rendertype=abstract Accessed 31 January 2013..
2. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3079639&tool=pmcentrez&rendertype=abstract. Accessed 29 January 2013.
3. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. (2012) Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 367: 399-410. Available: http://www.ncbi.nlm.nih.gov/pubmed/22784037. Accessed 22 May 2013.
4. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, et al. (2013) Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebocontrolled phase 3 trial. Lancet 381: 2083-2090. Available: http://www.ncbi.nlm.nih.gov/pubmed/23769234. Accessed 30 October 2013.
5. Karim SSA, Kashuba ADM, Werner L, Karim QA (2011) Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 378: 279-281. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3652579&tool=pmcentrez&rendertype=abstract. Accessed 27 May 2013.
6. Anderson PL, Glidden D V, Liu A, Buchbinder S, Lama JR, et al. (2012) Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 4: 151ra125. Available: http://www.ncbi.nlm.nih.gov/pubmed/22972843. Accessed 18 July 2013.
7. Anton PA, Cranston RD, Kashuba A, Hendrix CW, Bumpus NN, et al. (2012) RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses 28: 1412-1421. Available: http://www.ncbi.nlm.nih.gov/pubmed/22943559. Accessed 31 January 2013.
8. Anton PA, Saunders T, Elliott J, Khanukhova E, Dennis R, et al. (2011) First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS One 6: e23243. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3182160&tool=pmcentrez&rendertype=abstract. Accessed 2013 July 18.
9. Louissaint NA, Cao Y-J, Skipper PL, Liberman RG, Tannenbaum SR, et al. (2013) Single Dose Pharmacokinetics of Oral Tenofovir in Plasma, Peripheral Blood Mononuclear Cells, Colonic Tissue, and Vaginal Tissue. AIDS Res Hum Retroviruses. Available: http://www.ncbi.nlm.nih.gov/pubmed/23600365. Accessed 2013 July 18.
10. Louissaint NA, Fuchs EJ, Bakshi RP, Nimmagadda S, Du Y, et al. (2012) Distribution of cell-free and cell-associated HIV surrogates in the female genital tract after simulated vaginal intercourse. J Infect Dis 205: 725-732. Available: http://www.ncbi.nlm.nih.gov/pubmed/22279121. Accessed 2013 July 18.
11. Beigi R, Noguchi L, Parsons T, Macio I, Kunjara Na Ayudhya RP, et al. (2011) Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy. J Infect Dis 204: 1527-1531. Available: http://www. pubmedcentral.nih.gov/articlerender.fcgi?artid=3192189&tool=pmcentrez&rendertype=abstract. Accessed 2013 July 18.
12. Keller MJ, Madan RP, Torres NM, Fazzari MJ, Cho S, et al. (2011) A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One 6: e16475. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3026837&tool=pmcentrez&rendertype=abstract. Accessed 2 February 2013.
13. King T, Bushman L, Kiser J, Anderson PL, Ray M, et al. (2006) Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J Chromatogr B Analyt Technol Biomed Life Sci 843: 147-156. Available: http://www.ncbi.nlm.nih.gov/pubmed/16828350. Accessed 2 February 2013.
14. Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, et al. (2013) MTN- 001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One 8: e55013. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3559346&tool=pmcentrez&rendertype=abstract. Accessed 27 May 2013.
15. R Core Team (2013) R: A Language and Environment for Statistical Computing. Available: http://www.r-project.org/.
16. Sarkar D (n.d.) Lattice: Multivariate Data Visualization with R (Use R!). Springer. Available: http://www.amazon.com/Lattice-Multivariate-Data-Visualization-Use/dp/0387759689. Accessed 2 February 2013.
17. Sarkar D, Andrews F (2012) latticeExtra: Extra Graphical Utilities Based on Lattice. Available: http://cran.r-project.org/package=latticeExtra.
18. Wickham H (2011) The split-apply-combine strategy for data analysis. J Statis. Available: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.182.5667&rep=rep1&type=pdf. Accessed 2 February 2013.
19. Wickham H (2007) Reshaping data with the reshape package. J Stat Softw. Available: http://www.had.co.nz/reshape/introduction.pdf. Accessed 2 February 2013.
20. Wang J, Zamar R, Marazzi A, Yohai V, Salibian-Barrera M, et al. (2013) robust: Robust Library. Available: http://cran.r-project.org/package=robust.
21. Hampel FR, Ronchetti EM, Rousseeuw PJ, Stahel WA (2005) Robust Statistics. Hoboken, NJ, USA: John Wiley & Sons, Inc.
22. Van Hoogdalem E, de Boer AG, Breimer DD (1991) Pharmacokinetics of rectal drug administration, Part I. General considerations and clinical applications of centrally acting drugs. Clin Pharmacokinet 21: 11-26. Available: http://www.ncbi.nlm.nih.gov/pubmed/1717195. Accessed 17 July 2013.
23. Van Hoogdalem EJ, de Boer AG, Breimer DD (1991) Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions. Clin Pharmacokinet 21: 110-128. Available: http://www.ncbi.nlm.nih.gov/pubmed/1884566. Accessed 17 July 2013.
24. De Boer AG, Moolenaar F, de Leede LG, Breimer DD (n.d.) Rectal drug administration: clinical pharmacokinetic considerations. Clin Pharmacokinet 7: 285-311. Available: http://www.ncbi.nlm.nih.gov/pubmed/6126289. Accessed 17 July 2013.
25. Fung HB, Stone EA, Piacenti FJ (2002) Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Clin Ther 24: 1515-1548. Available: http://www.ncbi.nlm.nih.gov/pubmed/12462284. Accessed 18 July 2013.
26. Kearney BP, Flaherty JF, Shah J (2004) Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 43: 595-612. Available: http://www.ncbi.nlm.nih.gov/pubmed/15217303. Accessed 18 July 2013.
27. Yáñez JA, Remsberg CM, Sayre CL, Forrest ML, Davies NM (2011) Flip-flop pharmacokinetics-delivering a reversal of disposition: challenges and opportunities during drug development. Ther Deliv 2: 643-672. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3152312&tool=pmcentrez&rendertype=abstract. Accessed 16 December 2013.
28. Van Ginneken CA, Russel FG (1989) Saturable pharmacokinetics in the renal excretion of drugs. Clin Pharmacokinet 16: 38-54. Available: http://www.ncbi.nlm.nih.gov/pubmed/2650954. Accessed 17 July 2013.
29. Rodríguez-Nóvoa S, Labarga P, Soriano V, Egan D, Albalater M, et al. (2009) Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 48: e108-16. Available: http://www.ncbi.nlm.nih.gov/pubmed/19400747. Accessed 17 July 2013.
30. Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, et al. (2007) Functional involvement of multidrug resistance-associated protein 4 (MRP4/ ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 71: 619-627. Available: http://www.ncbi.nlm.nih.gov/pubmed/17110501. Accessed 17 July 2013.
31. Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, et al. (2006) Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 50: 3297-3304. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1610069&tool=pmcentrez&rendertype=abstract. Accessed 30 May 2013.
32. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, et al. (2011) Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 3: 112re4. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3483088&tool=pmcentrez&rendertype=abstract. Accessed 31 May 2013.
33. Robbins BL, Wilcox CK, Fridland A, Rodman JH (2003) Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacotherapy 23: 695-701. Available: http://www.ncbi.nlm.nih.gov/pubmed/12820810. Accessed 18 July 2013.
34. Nuttall J, Kashuba A, Wang R, White N, Allen P, et al. (2012) Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques. Antimicrob Agents Chemother 56: 103-109. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3256015&tool=pmcentrez&rendertype=abstract. Accessed 18 July 2013.